Related Experiment Videos

Gene polymorphisms in APOE, NOS3, and LIPC genes may be risk factors for cardiac adverse events after primary CABG

Sandra Eifert1, Astrid Rasch, Andres Beiras-Fernandez

  • 1Department of Cardiac Surgery, Ludwig Maximilians University Munich, Germany. seifert@med.uni-muenchen.de

Journal of Cardiothoracic Surgery
|August 21, 2009
PubMed

Insights

Genetic predisposition influences coronary artery disease progression after coronary artery bypass grafting (CABG). A combined gene risk profile effectively stratified patient risk for adverse cardiac events, outperforming individual gene polymorphisms.

Area of Science:

  • Cardiovascular Genetics
  • Atherosclerosis Research
  • Surgical Outcomes

Background:

  • Coronary artery disease (CAD) progression post-coronary artery bypass grafting (CABG) may be influenced by genetic factors beyond traditional risk factors.
  • Understanding genetic predispositions can improve long-term patient management after CABG.

Purpose of the Study:

  • To investigate the association between specific gene polymorphisms and CAD progression in CABG patients.
  • To evaluate the utility of a combined gene risk profile for predicting adverse cardiac events post-CABG.

Main Methods:

  • 192 CABG patients were studied, with data on clinical outcomes and gene polymorphisms (ApoE, NOS3, LIPC, CETP, SERPINE-1, Prothrombin).
  • Adverse cardiac events included reoperation, reintervention, and angina, with a mean follow-up of 10.1 years.
  • Gene polymorphisms were analyzed individually and combined into a gene risk profile.

Main Results:

  • Arterial hypertension and hypercholesterinemia were significant risk factors for CAD progression.
  • Individual polymorphisms (ApoE, NOS3, LIPC) showed limited predictive value, though some associations were noted (e.g., ApoE epsilon 3 absence with reintervention).
  • A gene risk profile significantly differentiated between patients with faster and slower occurrence of adverse cardiac events (p = 0.0012).

Conclusions:

  • Single gene polymorphisms (APOE, LIPC, NOS3) offer limited prognostic capability for cardiac adverse events after CABG.
  • A comprehensive gene risk profile provides effective risk stratification for patients undergoing CABG.
Abstract

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...